Overview

Post-op T-DM1 in HER-2+ Salivary Gland Carcinomas

Status:
Recruiting

Trial end date:
2026-02-01

Target enrollment:

Participant gender:

Summary

This research is being done to see how safe and effective the use of the study drug Ado-trastuzumab (T) emtansine (DM1), T-DM1, and standard of care chemoradiation are when used together in treating HER2-positive salivary gland cancer. It will also examine the effectiveness of study drug Ado-trastuzumab (T) emtansine (DM1) on cancer recurrence.

Phase:

Phase 2

Details

Lead Sponsor:

Dana-Farber Cancer Institute

Collaborator:

Genentech, Inc.

Treatments:

Carboplatin
Cisplatin
Maytansine
Trastuzumab